Evidence map›Paper›PMID 30898204›Full record

Trial reportJournal of the American College of Cardiology2019

Effect of Testosterone on Natriuretic Peptide Levels.

Katherine N Bachmann, Shi Huang, Hang Lee, Laura E Dichtel, Deepak K Gupta, John C Burnett, Karen K Miller, Thomas J Wang, Joel S Finkelstein

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American College of Cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00114114 (Dose-Response of Gonadal Steroids and Bone Turnover in Older Men), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00114114 nacompletednot on this map

Dose-Response of Gonadal Steroids and Bone Turnover in Older Men

TypeinterventionalSponsorMassachusetts General HospitalRan2004 to 2017Enrolled177ConditionsHealthy VolunteersArmsTestosterone, Goserelin acetate
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Renal Tubule Cell-SpecificHypertension (Dallas, Tex. : 1979) · 2026
    Article
  3. Article
  4. Article
  5. Bone morphogenetic protein 10: clinical correlates and risk of incident atrial fibrillation.American journal of physiology. Heart and circulatory physiology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Sex-based differences in metabolic protection by the ANP genetic variant rs5068 in the general population.American journal of physiology. Heart and circulatory physiology · 2023
    Article
  11. Article
  12. Sex-Related Differences in Heart Failure Diagnosis.Current heart failure reports · 2023
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Katherine N BachmannVeterans Administration Tennessee Valley Healthcare System, Nashville, Tennessee; Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee. Electronic address: Katherine.n.bachmann@vanderbilt.edu.
Shi HuangVanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Hang LeeBiostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
Laura E DichtelNeuroendocrine Unit, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.
Deepak K GuptaVanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
John C BurnettCardiorenal Research Laboratory, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Karen K MillerNeuroendocrine Unit, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.
Thomas J WangVanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Joel S FinkelsteinEndocrine Unit, Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.
Vanderbilt University · USHarvard University · USMassachusetts General Hospital · USMayo Clinic · US

Funding

HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Sally W Thurston · 1985 to 2026
$42.8M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · NCRR · MASSACHUSETTS GENERAL HOSPITAL · PI HALL, JANET E · 1985 to 2008
$37.4M
TRAINING PROGRAM IN ENDOCRINOLOGY AND DIABETEST32DK007028 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Karen K Miller · 1986 to 2026
$18.5M
Translational Research in Endocrinology And Diabetes (TREAD)T32DK007061 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Sarah S Jaser, KEVIN D NISWENDER · 1986 to 2026
$8.0M
Physiologic effects of androgen and estrogen deficiency in young and old menR01AG030545 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI FINKELSTEIN, JOEL S · 2007 to 2011
$3.1M
Obesity, salt-sensitivity, and the natriuretic peptidesR01HL102780 · NHLBI · VANDERBILT UNIVERSITY · PI WANG, THOMAS J. · 2011 to 2014
$1.7M
Growth Hormone and Cardiovascular DiseaseK24HL092902 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · 2010 to 2019
$1.6M
EFFECTS OF ANDROGENS, ESTROGENS, AND PTH ON BONEK24DK002759 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI FINKELSTEIN, JOEL S · 1999 to 2008
$1.2M
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic SteatohepatitisK23DK113220 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI DICHTEL, LAURA ELISABETH · 2017 to 2021
$1.1M
The natriuretic peptide system in African-AmericansK23HL128928 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GUPTA, DEEPAK · 2016 to 2019
$737k
Metabolic Effects of Natriuretic Peptide HormonesIK2CX001678 · VA · VETERANS HEALTH ADMINISTRATION · PI BACHMANN, KATHERINE NEUBECKER · 2018 to 2022
–
CSRD VA IK2 CX001678NCRR NIH HHS M01 RR001066NCRR NIH HHS UL1 RR025758NHLBI NIH HHS K23 HL128928NHLBI NIH HHS K24 HL092902NHLBI NIH HHS R01 HL102780NIA NIH HHS R01 AG030545NIDDK NIH HHS K23 DK113220NIDDK NIH HHS K24 DK002759NIDDK NIH HHS T32 DK007028NIDDK NIH HHS T32 DK007061NIEHS NIH HHS P30 ES001247
6 · The paper itself

Abstract

backgroundCirculating natriuretic peptide (NP) levels are markedly lower in healthy men than women. A relative NP deficiency in men could contribute to their higher risk of hypertension and cardiovascular disease. Epidemiological studies suggest testosterone may contribute to sex-specific NP differences.

objectivesThis study aimed to determine the effect of testosterone administration on NP levels using a randomized, placebo-controlled design.

methodsOne hundred and fifty-one healthy men (20 to 50 years of age) received goserelin acetate to suppress endogenous production of gonadal steroids, and anastrazole to suppress conversion of testosterone to estradiol. Subjects were randomized to placebo gel or 4 different doses of testosterone (1%) gel for 12 weeks. Serum N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and total testosterone levels were measured at baseline and follow-up.

resultsMen who did not receive testosterone replacement (placebo gel group) after suppression of endogenous gonadal steroid production experienced a profound decrease in serum testosterone (median 540 to 36 ng/dl; p < 0.0001). This was accompanied by an increase in median NT-proBNP (+8 pg/ml; p = 0.02). Each 1-g increase in testosterone dose was associated with a 4.3% lower NT-proBNP at follow-up (95% confidence interval: -7.9% to -0.45%; p = 0.029). An individual whose serum testosterone decreased by 500 ng/dl had a 26% higher predicted follow-up NT-proBNP than someone whose serum testosterone remained constant.

conclusionsSuppression of testosterone production in men led to increases in circulating NT-proBNP, which were attenuated by testosterone replacement. Inhibition of NP production by testosterone may partly explain the lower NP levels in men. (Dose-Response of Gonadal Steroids and Bone Turnover in Men; NCT00114114).

Indexed as

TestosteroneAdministration, TopicalAdultAnastrozoleAndrogensAntineoplastic Agents, HormonalAromatase InhibitorsCorrelation of DataDrug MonitoringEstradiolGoserelinHealthy VolunteersHumansMaleMiddle AgedNatriuretic Peptide, BrainAnastrozoleAndrogensAntineoplastic Agents, HormonalAromatase InhibitorsEstradiolGoserelinNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)TestosteroneBNPcardiovascular riskhypertensionnatriuretic peptideNT-proBNPtestosterone

Identifiers

PMID30898204
PMCPMC6588352
OpenAlexW2921788281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.